Assenagon Asset Management S.A. Has $4.59 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Assenagon Asset Management S.A. trimmed its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 21.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 199,720 shares of the biopharmaceutical company’s stock after selling 52,949 shares during the period. Assenagon Asset Management S.A. owned 0.21% of Ultragenyx Pharmaceutical worth $4,594,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of RARE. Assetmark Inc. lifted its position in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares in the last quarter. Huntington National Bank increased its position in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares in the last quarter. Danske Bank A S bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth about $39,000. Smartleaf Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the last quarter. Finally, Covestor Ltd lifted its position in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Bank of America decreased their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. HC Wainwright reduced their price objective on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Robert W. Baird decreased their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Canaccord Genuity Group lowered their target price on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Finally, Truist Financial upgraded Ultragenyx Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $60.47.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Truist upgraded Ultragenyx to “strong-buy”, which could support the shares if follow‑through buying appears. Zacks/Truist upgrade
• Neutral Sentiment: Recent quarterly results were mixed: revenue beat estimates and grew year-over-year, but the company missed on EPS and remains unprofitable—results that leave room for differing analyst interpretations and volatility. (See recent company earnings release and estimates in coverage.)
• Negative Sentiment: Multiple securities‑litigation firms (Rosen, The Gross Law Firm, Faruqi & Faruqi, ClaimsFiler, Pomerantz and others) have issued shareholder alerts and reminders of an April 6, 2026 lead‑plaintiff deadline, signaling an active securities class action and increasing the risk of future legal costs and settlements. Rosen Law Firm notice ClaimsFiler notice Faruqi & Faruqi notice
• Negative Sentiment: Goldman Sachs downgraded Ultragenyx to Neutral and coverage noted the stock hit a new 12‑month low after the analyst move—an action that likely amplified selling pressure. Goldman Sachs downgrade 12‑month low report

Ultragenyx Pharmaceutical Price Performance

RARE opened at $19.38 on Monday. The firm has a 50 day simple moving average of $22.37 and a 200 day simple moving average of $28.04. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -3.32 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s revenue was up 25.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.39) earnings per share. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the completion of the sale, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at $15,025,063.20. The trade was a 7.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Erik Harris sold 10,539 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $240,289.20. Following the completion of the sale, the executive vice president owned 89,515 shares of the company’s stock, valued at $2,040,942. This represents a 10.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 104,873 shares of company stock worth $2,391,936 over the last three months. Insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.